Pharmaceuticals

Hereditary Angioedema Therapeutics Market Trends 2025–2029: Forecasts for Key Growth Segments

November 9, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Does The Market Size Of The Hereditary Angioedema Therapeutics Industry Compare Between 2025 And 2029?

The hereditary angioedema therapeutics market has seen rapid expansion in recent years. Its valuation is anticipated to rise from $6.68 billion in 2024 to $7.77 billion in 2025, reflecting a compound annual growth rate (CAGR) of 16.3%. The market’s past growth can be ascribed to improved diagnosis and public awareness, expanded access to treatments, various research and development initiatives, patient advocacy and educational efforts, and successful regulatory approvals.

The hereditary angioedema therapeutics market is projected to experience substantial expansion over the upcoming years. This market is set to reach $15.84 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 19.5%. The anticipated growth during this period stems from factors such as advancements in targeted therapies, expansion into global markets, breakthroughs in gene therapy, the increasing adoption of personalized medicine, and enhanced collaboration in both research and treatment efforts. Key trends identified for the forecast period encompass global access initiatives, extensive health economic outcomes research, the implementation of early intervention strategies, and the development of therapeutics specifically for pediatric HAE.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp

Which Factors And Drivers Are Influencing The Hereditary Angioedema Therapeutics Market In 2025?

The increasing occurrence of hereditary angioedema is anticipated to drive the expansion of the hereditary angioedema market in the foreseeable future. Hereditary angioedema, often abbreviated as HAE, is an uncommon inherited condition marked by repeated occurrences of intense swelling affecting the skin and internal lining tissues. This swelling results from an accumulation of surplus fluid, known as EDEMA, and has the potential to manifest in any part of the body, such as the hands, feet, face, digestive system, and respiratory passages. As an illustration, in June 2022, data from Rare Disease Advisor, an online platform for healthcare professionals, indicated that globally, 1 in every 50,000 persons suffer from hereditary angioedema, with prevalence estimates spanning from 1:10,000 to 1:150,000. Annually in the US, HAE episodes lead to 15,000 to 30,000 emergency room visits. A segment of HAE cases, specifically 5.8%, recorded an average diagnostic period of 0 to 6 months, while another 5.8% experienced an average diagnosis time exceeding over 10 years. Consequently, the growing incidence of hereditary angioedema is a key factor propelling the expansion of the hereditary angioedema market.

What Are The Key Segments In The Hereditary Angioedema Therapeutics Market?

The hereditary angioedema therapeutics market covered in this report is segmented –

1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes

2) By Route of Administration: Intravenous, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

4) By Application: Prophylaxis, On-demand

Subsegments:

1) By C1 Esterase Inhibitor: Plasma-Derived, Recombinant

2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant

3) By Kallikrein Inhibitor: Ecallantide, Lanadelumab

4) By Other Drug Classes: Emerging Therapies

What Trends Are Expected To Drive The Hereditary Angioedema Therapeutics Market?

Product innovations represent a significant and growing trend within the hereditary angioedema therapeutics market. Leading companies in the hereditary angioedema therapeutics market are developing cutting-edge products, such as ligand-conjugated (LICA) investigational antisense medicine and gene therapy, to solidify their market standing. For instance, in March 2023, Intellia Therapeutics, a clinical-stage biotechnology firm located in the US, introduced an Investigational New Drug (IND) called NTLA-2002. The United States Food and Drug Administration had approved this drug for treating hereditary angioedema. This development enables the company’s ongoing Phase 1/2 trial to extend its reach to encompass the US within the worldwide Phase 2 portion. Following a single therapeutic administration, the inactivation of the target gene, kallikrein B1 (KLKB1), is expected to result in a permanent reduction of plasma kallikrein protein activity, thereby preventing HAE attacks. NTLA-2002 is considered a candidate for in vivo genome editing.

Which Industry Leaders Are Driving Innovation Across The Hereditary Angioedema Therapeutics Market?

Major companies operating in the hereditary angioedema therapeutics market include Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG ., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Hereditary Angioedema Therapeutics Market?

North America was the largest region in the global hereditary angioedema therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Hereditary Angioedema Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=10810&type=smp

Browse Through More Reports Similar to the Global Hereditary Angioedema Therapeutics Market 2025, By The Business Research Company

Cold Pain Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cold-pain-therapy-global-market-report

Physical Therapy Software Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/physical-therapy-software-global-market-report

Vitamin D Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/vitamin-d-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795